Skip to search formSkip to main contentSkip to account menu

INT-767

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Faculty Opinions recommendation of Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis.
  • C. Aguilar-Salinas
  • Faculty Opinions – Post-Publication Peer Review…
  • 2019
  • Corpus ID: 132676172
2017
2017
A Dual Agonist of Farnesoid X Receptor (FXR) and the G protein-coupled Receptor TGR5, INT-767, Slows Down Age-Related Kidney Disease in Mice
Even in healthy individuals, renal function gradually declines during aging. However, an observed variation in the rate of this… 
2017
2017
The dual FXR/TGR5 agonist INT-767 counteracts nonalcoholic steatohepatitis and visceral adipose tissue dysfunction in a rabbit model of high fat diet-induced metabolic syndrome
2016
2016
The dual FXR/TGR5 agonist INT-767 counteracts nonalcoholic steatohepatitis in a rabbit model of high fat diet-induced metabolic syndrome
2016
2016
The dual FXR/TGR5 agonist INT-767 reduces visceral fat mass, promoting preadipocyte brown differentiation, mitochondrial function and insulin sensitivity in a rabbit model of high fat diet-induced…
2016
2016
SCALE-UP SYNTHESIS OF 3α,7α,23-TRIHYDROXY-6α-ETHYL-24-NOR-5β-CHOLAN-23-SULFATE SODIUM SALT (INT-767), A POTENT FXR/TGR5 DUAL AGONIST IN PHASE I CLINICAL STUDIES
2014
2014
INT-767 inhibits systemic and local inflammation in ApoE−/− mice.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)